Combotope Therapeutics ApS has established a strategic research collaboration with Boehringer Ingelheim Pharma GmbH & Co. KG that will leverage Combotope’s proprietary SMART-Phage platform to generate highly tumor-selective antibodies for next-generation cancer therapies.
Investigators from the Karl Landsteiner University aimed to evaluate the therapeutic potential of a novel CDK9 inhibitor/degrader, GT-02897, for the potential treatment of multiple myeloma.
Midkine (MDK) is a multifunctional heparin-binding cytokine highly overexpressed and extracellularly enriched in the tumor microenvironment (TME) of several cancers.
Researchers from Bristol Myers Squibb Co. (BMS) presented preclinical data on BMS-986453 (tunlucabtagene autoleucel), a dual-targeting BCMA×GPRC5D CAR T-cell therapy, in models of multiple myeloma.
Ascletis Pharma Inc. has received IND clearance from the FDA for ASC-35, a once-monthly subcutaneously administered GLP-1 receptor (GLP-1R)/GIP receptor (GIPR) dual peptide agonist, for the treatment of obesity.
RQ Biotechnology Ltd. has completed an oversubscribed $115 million (£85.5 million) series A financing to advance its long-acting antibody therapeutics for the prevention of influenza in high-risk and immunocompromised populations.
Unixell Biotechnology Co. Ltd. has obtained IND clearance from the FDA for UX-DA003, its allogeneic induced pluripotent stem cell (iPSC)-derived therapy for Parkinson’s disease. IND approval was also gained in China earlier this month, enabling concurrent clinical development in both China and the U.S.
X-tosis Inc. has been awarded a $2.74 million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to support advancement of XTS-001, the lead candidate from the company’s Mitoxts platform, toward clinical development for the treatment of Parkinson’s disease. The grant will support confirmatory studies, biomarker development and IND-enabling work.
Some proteins embedded in the structure of prions may have antimicrobial activity, according to a study led by scientists at the University of Pennsylvania. An AI analysis of millions of fragments from prion-related proteins has revealed more than a thousand peptides that disrupt bacterial membranes and reduce infection in animal models, suggesting these proteins could be an unexpected source of new antibiotics.
RSS
